Updated:
Incyte Corporation
Incyte is a global biopharmaceutical company focused on finding innovative solutions for serious unmet medical needs through the discovery, development and...
Incyte Corporation
Incyte is a global biopharmaceutical company focused on finding innovative solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines..
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Wilmington
Corporate office
Wilmington, DE, United States
Sector focus
Frequently asked questions
How does Incyte fund its research and development?
Incyte operates as an integrated pharmaceutical company, funding its R&D through a corporate balance sheet and revenue from commercialized products. It does not operate as an investment manager raising external capital. Revenue is generated directly from drug sales across its three core therapeutic franchises.
In which therapeutic areas does Incyte concentrate its development efforts?
Incyte focuses on three core therapeutic areas: hematology, oncology, and inflammation and autoimmunity, including dermatology. The firm maintains clinical programs across these areas, along with partnered programs that extend its research scope.
Does Incyte participate in partnered programs or does it only develop assets internally?
Incyte develops assets both internally and through partnered programs. Its website highlights a portfolio spanning wholly owned clinical programs across its core franchises, as well as partnered programs that broaden its therapeutic reach.
What is Incyte's latest approved product?
According to a firm press release, the FDA recently approved Jakafi XR (ruxolitinib) extended-release tablets for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
How does Incyte commercialize its products?
Incyte commercializes its products globally through a direct sales model. Drugs are developed internally and then distributed by the firm to address serious unmet medical needs, rather than licensing them to a separate commercial entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: